The estimated Net Worth of Phillip A Sharp is at least $30.3 Million dollars as of 29 February 2024. Phillip Sharp owns over 30,000 units of Alnylam Pharmaceuticals Inc stock worth over $7,857,300 and over the last 21 years he sold ALNY stock worth over $21,935,627. In addition, he makes $495,707 as Independent Director at Alnylam Pharmaceuticals Inc.
Sign up
Phillip Sharp ALNY stock SEC Form 4 insiders trading
Phillip has made over 19 trades of the Alnylam Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 30,000 units of ALNY stock worth $1,777,500 on 29 February 2024.
The largest trade he's ever made was selling 294,100 units of Alnylam Pharmaceuticals Inc stock on 14 May 2004 worth over $17,281,316. On average, Phillip trades about 11,038 units every 93 days since 2003. As of 29 February 2024 he still owns at least 30,000 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of Phillip Sharp stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Phillip Sharp biography
Dr. Phillip A. Sharp Ph.D. is Independent Director of Alnylam Pharmaceuticals, Inc. Dr. Sharp is a scientific founder of Alnylam and has served as a member of our board of directors since June 2002. Dr. Sharp is an Institute Professor at the David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), and was the Founding Director of the McGovern Institute for Brain Research at MIT. Dr. Sharp has been a professor at MIT since 1974. He is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences. Dr. Sharp also serves as a director of Syros Pharmaceuticals, Inc. and formerly served as a director of Biogen Inc., which he co-founded in 1978.
What is the salary of Phillip Sharp?
As the Independent Director of Alnylam Pharmaceuticals Inc, the total compensation of Phillip Sharp at Alnylam Pharmaceuticals Inc is $495,707. There are 13 executives at Alnylam Pharmaceuticals Inc getting paid more, with John Maraganore having the highest compensation of $7,317,860.
How old is Phillip Sharp?
Phillip Sharp is 75, he's been the Independent Director of Alnylam Pharmaceuticals Inc since 2002. There are no older and 20 younger executives at Alnylam Pharmaceuticals Inc.
What's Phillip Sharp's mailing address?
Phillip's mailing address filed with the SEC is 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142.
Insiders trading at Alnylam Pharmaceuticals Inc
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal, and Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.
What does Alnylam Pharmaceuticals Inc do?
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
What does Alnylam Pharmaceuticals Inc's logo look like?
Complete history of Phillip Sharp stock trades at Alnylam Pharmaceuticals Inc, Biogen Inc, Syros Pharmaceuticals, and Vir Biotechnology Inc
Alnylam Pharmaceuticals Inc executives and stock owners
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
John Maraganore,
Chief Executive Officer, Director -
Jeffrey Poulton,
Chief Financial Officer, Executive Vice President -
Laurie Keating,
Executive Vice President, Chief Legal Officer, Secretary -
Yvonne Greenstreet,
President, Chief Operating Officer -
Akshay Vaishnaw,
President - Research and Development -
Dr. John M. Maraganore M.D., Ph.D.,
CEO & Exec. Director -
Margaret Hamburg,
Independent Director -
Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB,
Pres, COO & Director -
Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBA,
Pres & COO -
Dr. Akshay K. Vaishnaw,
Pres of R&D -
Jeffrey V. Poulton M.B.A.,
CFO & Exec. VP -
Laurie Bartlett Keating J.D.,
Exec. VP, Chief Legal Officer & Sec. -
Michael Bonney,
Independent Chairman of the Board -
Phillip Sharp,
Independent Director -
Marsha Fanucci,
Independent Director -
Amy Schulman,
Independent Director -
Steven Paul,
Independent Director -
Colleen Reitan,
Independent Director -
David Pyott,
Independent Director -
Dennis Ausiello,
Independent Director -
Michael W. Bonney B.A.,
Exec. Chairman -
Olivier Brandicourt,
Director -
Kevin Fitzgerald,
Senior Vice President, Chief Scientific Officer -
Kelley Boucher,
Chief Human Resource Officer, Senior Vice President -
Arianna Greco,
Interim Chief Legal officer -
Mark Baglin,
VP of Global Marketing -
Agnieszka Gallagher,
Chief Ethics & Compliance Officer -
Christine Regan Lindenboom,
Sr. VP of Investor Relations & Corp. Communications -
Dr. Alfred W. Boyle Ph.D.,
Chief Technical Operations & Quality Officer -
David Alexandre C Gros,
SVP, Chief Business Officer -
Kevin P Starr,
Director -
Paul Schimmel,
Director -
Sanofi,
10% owner -
Michael Mason,
VP, Finance and Treasurer -
John K Clarke,
Director -
Barry E Greene,
President -
Manmeet Singh Soni,
Chief Financial Officer -
Carolyn R Bertozzi,
Director -
Pushkal Garg,
CMO & EVP Dev & Med Affairs -
Peter N Kellogg,
Director -
Venture Management Co Iii L...,
10% owner -
Victor J Dzau,
Director -
Agnovartis Pharma Ag Novartis,
-
Venture Management Co Iii L...,
-
Peter Barrett,
Director -
Christoph H Westphal,
Director -
Venture Fund V Lpatlas Vent...,
-
Venture Management Co Iii L...,
-
Ii Lp Chp,
10% owner -
Kenneth S Koblan,
Chief Scientific Officer -
Laurence Reid,
SVP, Chief Business Officer -
Vicki L Sato,
Director -
Management Ltd Abingworth,
10% owner -
John A Jr Schmidt,
SVP, Chief Scientific Officer -
Patricia L Allen,
VP Finance and Treasurer -
Venture Fund V Lpatlas Vent...,
-
John E Berriman,
Director -
Vincent J Miles,
Senior VP Business Development -
James L Vincent,
Director -
Venture Fund V Lpatlas Vent...,
-
Edward M Scolnick,
Director -
Tolga Tanguler,
EVP, Chief Commercial Officer -
Charles Elliott Sigal,
Director